ResMed Q3 FY2024 revenue $1.20B, +7% YoY; GAAP EPS $2.04, non-GAAP $2.13

RESMED INC

2024-Q3 EPS reported $4.94 revenue$3,462,102,000

Revenue $1.197B up 7% YoY (7% constant currency); mask/accessories double-digit growth.
Gross margin expanded 260 bps to 57.9%; non-GAAP 58.5%.
Operating profit $374.6M (+25%); non-GAAP operating profit $393.6M (+23%).
Diluted GAAP EPS $2.04 (+29%); non-GAAP EPS $2.13 (+27%).
Quarterly dividend $0.48, record May 9, payable June 13.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RESMED INC reported the quarter ended March 31, 2024 results: revenue $1.2 billion, EPS $2.04.

Period: the quarter ended March 31, 2024
Revenue: $1.2 billion
EPS: $2.04
Result: reported results

Exact text from the filing

he prior year period • Revenue increased by 7% to $1.2 billion; up 7% on a constant currency basis • Gross margin grew 260 bps to 57.9%; non-GAAP gross margin grew

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-24-113883

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.